{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T11:09:54Z","timestamp":1789816194986,"version":"4.0.1"},"reference-count":119,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"vor","delay-in-days":40,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.neurot.2026.e00859","type":"journal-article","created":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T21:03:49Z","timestamp":1771967029000},"page":"e00859","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Silmitasertib, an FDA-designated orphan CK2 inhibitor, ameliorates neuropathology and motor dysfunction in a Huntington's disease mouse model"],"prefix":"10.1016","volume":"23","author":[{"given":"Ross J.","family":"Pelzel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miaya","family":"Herbst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas B.","family":"Rozema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa A.","family":"Solem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rocio","family":"Gomez-Pastor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.neurot.2026.e00859_bib1","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-E","article-title":"A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's disease collaborative research group","volume":"72","year":"1993","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00859_bib2","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1750-1326-1-19","article-title":"Multiple pathways contribute to the pathogenesis of Huntington disease","volume":"1","author":"Li","year":"2006","journal-title":"Mol Neurodegener"},{"issue":"4","key":"10.1016\/j.neurot.2026.e00859_bib3","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/j.1750-3639.1992.tb00709.x","article-title":"New insights into the clinical features, pathogenesis and molecular genetics of Huntington disease","volume":"2","author":"Kremer","year":"1992","journal-title":"Brain Pathol"},{"key":"10.1016\/j.neurot.2026.e00859_bib4","article-title":"Neuroinflammation in Huntington's disease: from animal models to clinical therapeutics","volume":"13","author":"Jia","year":"2022","journal-title":"Front Immunol [Internet]"},{"issue":"8083","key":"10.1016\/j.neurot.2026.e00859_bib6","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/d41586-025-03139-9","article-title":"Huntington's disease treated for first time using gene therapy","volume":"646","author":"Dolgin","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.neurot.2026.e00859_bib7","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2023.1094503","article-title":"Striatal spatial heterogeneity, clustering, and white matter association of GFAP+ astrocytes in a mouse model of Huntington's disease","volume":"17","author":"Brown","year":"2023","journal-title":"Front Cell Neurosci"},{"issue":"3","key":"10.1016\/j.neurot.2026.e00859_bib8","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1177\/18796397251344173","article-title":"The role of astrocytes in human Huntington's disease pathology","volume":"14","author":"Al-Dalahmah","year":"2025","journal-title":"J Huntingtons Dis"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00859_bib9","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s40478-020-0880-6","article-title":"Single-nucleus RNA-seq identifies Huntington disease astrocyte states","volume":"8","author":"Al-Dalahmah","year":"2020","journal-title":"Acta Neuropathol Commun"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00859_bib10","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1093\/brain\/awac068","article-title":"Reactive astrocytes promote proteostasis in Huntington's disease through the JAK2-STAT3 pathway","volume":"146","author":"Abjean","year":"2023","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00859_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2022.105732","article-title":"Single-nuclei transcriptome analysis of Huntington disease iPSC and mouse astrocytes implicates maturation and functional deficits","volume":"26","author":"Reyes-Ortiz","year":"2023","journal-title":"iScience"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00859_bib12","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/nyas.14977","article-title":"Astrocytic contributions to Huntington's disease pathophysiology","volume":"1522","author":"Khakh","year":"2023","journal-title":"Ann N Y Acad Sci"},{"issue":"514","key":"10.1016\/j.neurot.2026.e00859_bib13","doi-asserted-by":"crossref","first-page":"8546","DOI":"10.1126\/scitranslmed.aaw8546","article-title":"Astrocyte molecular signatures in Huntington's disease","volume":"11","author":"Diaz-Castro","year":"2019","journal-title":"Sci Transl Med"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00859_bib14","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s13311-023-01357-5","article-title":"Contribution of glial cells to polyglutamine diseases: observations from patients and mouse models","volume":"20","author":"Cvetanovic","year":"2023","journal-title":"Neurotherapeutics"},{"issue":"3","key":"10.1016\/j.neurot.2026.e00859_bib15","first-page":"487","article-title":"Mutant huntingtin reduction in astrocytes slows disease progression in the BACHD conditional Huntington's disease mouse model","volume":"28","author":"Wood","year":"2019","journal-title":"Hum Mol Genet"},{"issue":"12","key":"10.1016\/j.neurot.2026.e00859_bib16","doi-asserted-by":"crossref","first-page":"3453","DOI":"10.1523\/JNEUROSCI.3693-15.2016","article-title":"Dysfunctional calcium and glutamate signaling in striatal astrocytes from Huntington's disease model mice","volume":"36","author":"Jiang","year":"2016","journal-title":"J Neurosci"},{"issue":"11","key":"10.1016\/j.neurot.2026.e00859_bib17","doi-asserted-by":"crossref","DOI":"10.1242\/dmm.052002","article-title":"Modulation of SNARE-dependent exocytosis in astrocytes improves neuropathology in Huntington's disease","volume":"17","author":"King","year":"2024","journal-title":"Dis Model Mech"},{"key":"10.1016\/j.neurot.2026.e00859_bib18","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/978-981-13-9913-8_14","article-title":"Astrocytes in Huntington's disease","volume":"1175","author":"Gray","year":"2019","journal-title":"Adv Exp Med Biol"},{"issue":"Pt 1","key":"10.1016\/j.neurot.2026.e00859_bib19","first-page":"1","article-title":"Protein kinase CK2: structure, regulation and role in cellular decisions of life and death","volume":"369","author":"Litchfield","year":"2003","journal-title":"Biochem J"},{"issue":"4","key":"10.1016\/j.neurot.2026.e00859_bib20","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/S1357-2725(96)00142-2","article-title":"Protein kinase CK2","volume":"29","author":"Pinna","year":"1997","journal-title":"Int J Biochem Cell Biol"},{"issue":"Pt 9","key":"10.1016\/j.neurot.2026.e00859_bib21","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1242\/jcs.081778","article-title":"Protein kinase CK2 regulates the formation and clearance of aggresomes in response to stress","volume":"124","author":"Watabe","year":"2011","journal-title":"J Cell Sci"},{"issue":"8","key":"10.1016\/j.neurot.2026.e00859_bib22","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1007\/s00109-008-0352-0","article-title":"Protein kinase CK2, an important regulator of the inflammatory response?","volume":"86","author":"Singh","year":"2008","journal-title":"J Mol Med"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00859_bib23","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/s41392-021-00567-7","article-title":"Protein kinase CK2: a potential therapeutic target for diverse human diseases","volume":"6","author":"Borgo","year":"2021","journal-title":"Sig Transduct Target Ther"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00859_bib24","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms14405","article-title":"Abnormal degradation of the neuronal stress-protective transcription factor HSF1 in Huntington's disease","volume":"8","author":"Gomez-Pastor","year":"2017","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00859_bib25","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s40478-022-01379-8","article-title":"CK2 alpha prime and alpha-synuclein pathogenic functional interaction mediates synaptic dysregulation in Huntington's disease","volume":"10","author":"Yu","year":"2022","journal-title":"Acta Neuropathol Commun"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00859_bib26","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1053\/j.seminoncol.2018.04.006","article-title":"CIGB-300: a peptide-based drug that impairs the Protein Kinase CK2-mediated phosphorylation","volume":"45","author":"Perea","year":"2018","journal-title":"Semin Oncol"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00859_bib27","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-75990-1","article-title":"CIGB-300 internalizes and impairs viability of NSCLC cells lacking actionable targets by inhibiting casein kinase-2 signaling","volume":"14","author":"Yi","year":"2024","journal-title":"Sci Rep"},{"issue":"6","key":"10.1016\/j.neurot.2026.e00859_bib28","doi-asserted-by":"crossref","first-page":"4009","DOI":"10.1021\/acs.jmedchem.2c01887","article-title":"Silmitasertib (CX-4945), a clinically used CK2-Kinase inhibitor with additional effects on GSK3\u03b2 and DYRK1A kinases: a structural perspective","volume":"66","author":"Grygier","year":"2023","journal-title":"J Med Chem"},{"issue":"6","key":"10.1016\/j.neurot.2026.e00859_bib29","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1007\/s13402-020-00566-w","article-title":"Role of CK2 inhibitor CX-4945 in anti-cancer combination therapy \u2013 potential clinical relevance","volume":"43","author":"D'Amore","year":"2020","journal-title":"Cell Oncol"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00859_bib30","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3390\/ph10010018","article-title":"CK2 in cancer: cellular and biochemical mechanisms and potential therapeutic target","volume":"10","author":"Chua","year":"2017","journal-title":"Pharmaceuticals"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00859_bib31","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/s10020-024-00937-1","article-title":"Impact of protein kinase CK2 downregulation and inhibition on oncomir clusters 17 \u223c 92 and 106b \u223c 25 in prostate, breast, and head and neck cancers","volume":"30","author":"Kren","year":"2024","journal-title":"Mol Med"},{"key":"10.1016\/j.neurot.2026.e00859_bib32","doi-asserted-by":"crossref","first-page":"146","DOI":"10.3389\/fnmol.2018.00146","article-title":"CK2 phosphorylating I2PP2A\/SET mediates tau pathology and cognitive impairment","volume":"11","author":"Zhang","year":"2018","journal-title":"Front Mol Neurosci"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00859_bib33","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s40478-022-01331-w","article-title":"Inhibition of CK2 mitigates Alzheimer's tau pathology by preventing NR2B synaptic mislocalization","volume":"10","author":"Marshall","year":"2022","journal-title":"Acta Neuropathol Commun"},{"key":"10.1016\/j.neurot.2026.e00859_bib34","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3389\/fnmol.2014.00057","article-title":"Parkinson's disease-implicated kinases in the brain; insights into disease pathogenesis","volume":"7","author":"Dzamko","year":"2014","journal-title":"Front Mol Neurosci"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00859_bib35","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jns.2007.08.027","article-title":"Localization of CKII \u03b2 subunits in lewy bodies of Parkinson's disease","volume":"266","author":"Ryu","year":"2008","journal-title":"J Neurol Sci"},{"issue":"15","key":"10.1016\/j.neurot.2026.e00859_bib36","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1016\/j.neuron.2025.04.027","article-title":"Selective removal of astrocytic PERK protects against glymphatic impairment and decreases toxic aggregation of \u03b2-amyloid and tau","volume":"113","author":"Chen","year":"2025","journal-title":"Neuron"},{"issue":"12","key":"10.1016\/j.neurot.2026.e00859_bib37","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0049838","article-title":"Comprehensive behavioral and molecular characterization of a new knock-in mouse model of Huntington's disease: zQ175","volume":"7","author":"Menalled","year":"2012","journal-title":"PLoS One"},{"issue":"43","key":"10.1016\/j.neurot.2026.e00859_bib38","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abg4980","article-title":"Microglia become hypofunctional and release metalloproteases and tau seeds when phagocytosing live neurons with P301S tau aggregates","volume":"7","author":"Brelstaff","year":"2021","journal-title":"Sci Adv"},{"issue":"9","key":"10.1016\/j.neurot.2026.e00859_bib39","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1002\/glia.24039","article-title":"Histamine triggers microglial responses indirectly via astrocytes and purinergic signaling","volume":"69","author":"Xia","year":"2021","journal-title":"Glia"},{"issue":"8","key":"10.1016\/j.neurot.2026.e00859_bib40","doi-asserted-by":"crossref","first-page":"10468","DOI":"10.1007\/s12035-025-04905-6","article-title":"Estradiol mediates Astrocyte-Neuron communication in the hippocampus","volume":"62","author":"Goenaga","year":"2025","journal-title":"Mol Neurobiol"},{"issue":"6","key":"10.1016\/j.neurot.2026.e00859_bib41","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.neuron.2019.12.026","article-title":"Dopamine-evoked synaptic regulation in the nucleus accumbens requires astrocyte activity","volume":"105","author":"Corkrum","year":"2020","journal-title":"Neuron"},{"issue":"23","key":"10.1016\/j.neurot.2026.e00859_bib42","doi-asserted-by":"crossref","first-page":"6484","DOI":"10.1158\/1078-0432.CCR-13-0265","article-title":"Targeting protein kinase CK2 suppresses pro-survival signaling pathways and growth of glioblastoma","volume":"19","author":"Zheng","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"1\u20132","key":"10.1016\/j.neurot.2026.e00859_bib43","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1101\/gad.319830.118","article-title":"Regulation of MLL\/COMPASS stability through its proteolytic cleavage by taspase1 as a possible approach for clinical therapy of leukemia","volume":"33","author":"Zhao","year":"2019","journal-title":"Genes Dev"},{"issue":"2","key":"10.1016\/j.neurot.2026.e00859_bib44","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1007\/s13311-012-0112-2","article-title":"Huntington's disease and the striatal medium spiny neuron: cell-autonomous and non-cell-autonomous mechanisms of disease","volume":"9","author":"Ehrlich","year":"2012","journal-title":"Neurotherapeutics"},{"issue":"12","key":"10.1016\/j.neurot.2026.e00859_bib45","doi-asserted-by":"crossref","first-page":"6809","DOI":"10.1073\/pnas.120166397","article-title":"Severe deficiencies in dopamine signaling in presymptomatic Huntington's disease mice","volume":"97","author":"Bibb","year":"2000","journal-title":"Proc Natl Acad Sci"},{"issue":"12","key":"10.1016\/j.neurot.2026.e00859_bib46","article-title":"Complementary insights into corticostriatal synapse loss and cognition in Huntington's disease","volume":"4","author":"Hamilton","year":"2023","journal-title":"CR Med [Internet]"},{"key":"10.1016\/j.neurot.2026.e00859_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2021.105574","article-title":"Synaptic pathology in Huntington's disease: beyond the corticostriatal pathway","volume":"162","author":"Barry","year":"2022","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.neurot.2026.e00859_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2024.106752","article-title":"Corticostriatal maldevelopment in the R6\/2 mouse model of juvenile Huntington's disease","volume":"204","author":"Cepeda","year":"2025","journal-title":"Neurobiol Dis"},{"issue":"7","key":"10.1016\/j.neurot.2026.e00859_bib49","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.bbadis.2016.04.002","article-title":"Loss of striatal 90-kDa ribosomal S6 kinase (Rsk) is a key factor for motor, synaptic and transcription dysfunction in Huntington's disease","volume":"1862","author":"Anglada-Huguet","year":"2016","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00859_bib50","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13041-019-0456-1","article-title":"Modulation of mTOR and CREB pathways following mGluR5 blockade contribute to improved Huntington's pathology in zQ175 mice","volume":"12","author":"Abd-Elrahman","year":"2019","journal-title":"Mol Brain"},{"key":"10.1016\/j.neurot.2026.e00859_bib51","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2022.824956","article-title":"Evaluation of a selective chemical probe validates that CK2 mediates neuroinflammation in a human induced pluripotent stem cell-derived microglial model","author":"Mishra","year":"2022","journal-title":"Front Mol Neurosci [Internet]"},{"key":"10.1016\/j.neurot.2026.e00859_bib52","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.590266","article-title":"Myeloid cell CK2 regulates inflammation and resistance to bacterial infection","author":"Larson","year":"2020","journal-title":"Front Immunol [Internet]"},{"key":"10.1016\/j.neurot.2026.e00859_bib53","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3389\/fnagi.2017.00193","article-title":"Microglial activation in the pathogenesis of Huntington's disease","volume":"9","author":"Yang","year":"2017","journal-title":"Front Aging Neurosci"},{"key":"10.1016\/j.neurot.2026.e00859_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2020.104963","article-title":"The contribution of glial cells to Huntington's disease pathogenesis","volume":"143","author":"Wilton","year":"2020","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.neurot.2026.e00859_bib55","article-title":"Circulating levels of inflammatory biomarkers in Huntington's disease: a systematic review and meta-analysis","volume":"385","author":"Soltani","year":"2023","journal-title":"J Neuroimmunol"},{"issue":"3","key":"10.1016\/j.neurot.2026.e00859_bib56","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1177\/18796397251338207","article-title":"Neuroinflammation in Huntington's disease: causes, consequences, and treatment strategies","volume":"14","author":"Blusch","year":"2025","journal-title":"J Huntingtons Dis"},{"key":"10.1016\/j.neurot.2026.e00859_bib57","article-title":"Microglia morphophysiological diversity and its implications for the CNS","volume":"13","author":"Vidal-Itriago","year":"2022","journal-title":"Front Immunol [Internet]"},{"key":"10.1016\/j.neurot.2026.e00859_bib58","article-title":"Astrocyte heterogeneity and gliosis in Huntington's disease: histopathological insights into striatal and white matter pathology","author":"Pelzel","year":"2025","journal-title":"Histol Histopathol"},{"issue":"6","key":"10.1016\/j.neurot.2026.e00859_bib59","doi-asserted-by":"crossref","first-page":"4037","DOI":"10.1073\/pnas.052020999","article-title":"Glial protein S100B modulates long-term neuronal synaptic plasticity","volume":"99","author":"Nishiyama","year":"2002","journal-title":"Proc Natl Acad Sci"},{"issue":"6","key":"10.1016\/j.neurot.2026.e00859_bib60","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1002\/jemt.10303","article-title":"S100B in brain damage and neurodegeneration","volume":"60","author":"Rothermundt","year":"2003","journal-title":"Microsc Res Tech"},{"key":"10.1016\/j.neurot.2026.e00859_bib61","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.neubiorev.2021.04.035","article-title":"Growing role of S100B protein as a putative therapeutic target for neurological- and nonneurological-disorders","volume":"127","author":"Michetti","year":"2021","journal-title":"Neurosci Biobehav Rev"},{"issue":"8","key":"10.1016\/j.neurot.2026.e00859_bib62","doi-asserted-by":"crossref","first-page":"4085","DOI":"10.3390\/ijms22084085","article-title":"Emerging roles of exosomes in Huntington's disease","volume":"22","author":"Ananbeh","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"8","key":"10.1016\/j.neurot.2026.e00859_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.112998","article-title":"Chaperone-mediated autophagy in neuronal dendrites utilizes activity-dependent lysosomal exocytosis for protein disposal","volume":"42","author":"Grochowska","year":"2023","journal-title":"Cell Rep"},{"key":"10.1016\/j.neurot.2026.e00859_bib64","doi-asserted-by":"crossref","unstructured":"Donnelly KM, DeLorenzo OR, Zaya AD, Pisano GE, Thu WM, Luo L, et al. Phagocytic glia are obligatory intermediates in transmission of mutant huntingtin aggregates across neuronal synapses. eLife. 9:e58499.","DOI":"10.7554\/eLife.58499"},{"key":"10.1016\/j.neurot.2026.e00859_bib65","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s13024-025-00870-9","article-title":"Glial phagocytosis for synapse and toxic proteins in neurodegenerative diseases","volume":"20","author":"Choi","year":"2025","journal-title":"Mol Neurodegener"},{"issue":"4","key":"10.1016\/j.neurot.2026.e00859_bib66","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0196153","article-title":"Phagocytic response of astrocytes to damaged neighboring cells","volume":"13","author":"Wakida","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.neurot.2026.e00859_bib67","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s40035-023-00372-y","article-title":"\u03b1-Synuclein-carrying astrocytic extracellular vesicles in Parkinson pathogenesis and diagnosis","volume":"12","author":"Wang","year":"2023","journal-title":"Transl Neurodegener"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00859_bib68","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41467-017-00037-1","article-title":"Reactive astrocytes function as phagocytes after brain ischemia via ABCA1-mediated pathway","volume":"8","author":"Morizawa","year":"2017","journal-title":"Nat Commun"},{"issue":"10","key":"10.1016\/j.neurot.2026.e00859_bib69","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1111\/cns.14223","article-title":"Megf10-related engulfment of excitatory postsynapses by astrocytes following severe brain injury","volume":"29","author":"Zhuang","year":"2023","journal-title":"CNS Neurosci Ther"},{"issue":"4","key":"10.1016\/j.neurot.2026.e00859_bib70","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1093\/hmg\/ddu522","article-title":"Depletion of p62 reduces nuclear inclusions and paradoxically ameliorates disease phenotypes in Huntington's model mice","volume":"24","author":"Kurosawa","year":"2015","journal-title":"Hum Mol Genet"},{"issue":"5","key":"10.1016\/j.neurot.2026.e00859_bib71","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1007\/s10571-010-9507-y","article-title":"The evolutionarily conserved interaction between LC3 and p62 selectively mediates autophagy-dependent degradation of mutant huntingtin","volume":"30","author":"Tung","year":"2010","journal-title":"Cell Mol Neurobiol"},{"issue":"21","key":"10.1016\/j.neurot.2026.e00859_bib72","doi-asserted-by":"crossref","DOI":"10.3390\/ijms252111661","article-title":"CK and LRRK2 involvement in neurodegenerative diseases","volume":"25","author":"Bova","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00859_bib73","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-021-00567-7","article-title":"Protein kinase CK2: a potential therapeutic target for diverse human diseases","volume":"6","author":"Borgo","year":"2021","journal-title":"Sig Transduct Target Ther"},{"issue":"8","key":"10.1016\/j.neurot.2026.e00859_bib74","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.3390\/biomedicines10081979","article-title":"Protein kinase CK2 and its potential role as a therapeutic target in Huntington's disease","volume":"10","author":"White","year":"2022","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00859_bib75","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/nrm.2017.73","article-title":"Regulation of heat shock transcription factors and their roles in physiology and disease","volume":"19","author":"Gomez-Pastor","year":"2018","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"7","key":"10.1016\/j.neurot.2026.e00859_bib76","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nchembio.582","article-title":"Kinase inhibitors modulate huntingtin cell localization and toxicity","volume":"7","author":"Atwal","year":"2011","journal-title":"Nat Chem Biol"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00859_bib77","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.celrep.2018.09.015","article-title":"Cell-Autonomous regulation of astrocyte activation by the circadian clock protein BMAL1","volume":"25","author":"Lananna","year":"2018","journal-title":"Cell Rep"},{"issue":"574","key":"10.1016\/j.neurot.2026.e00859_bib78","doi-asserted-by":"crossref","first-page":"eaax3519","DOI":"10.1126\/scitranslmed.aax3519","article-title":"Chi3l1\/YKL-40 is controlled by the astrocyte circadian clock and regulates neuroinflammation and Alzheimer's disease pathogenesis","volume":"12","author":"Lananna","year":"2020","journal-title":"Sci Transl Med"},{"issue":"20","key":"10.1016\/j.neurot.2026.e00859_bib79","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2220551120","article-title":"Circadian clock protein BMAL1 broadly influences autophagy and endolysosomal function in astrocytes","volume":"120","author":"McKee","year":"2023","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"15","key":"10.1016\/j.neurot.2026.e00859_bib80","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1016\/j.neuron.2023.05.006","article-title":"An astrocyte BMAL1-BAG3 axis protects against alpha-synuclein and tau pathology","volume":"111","author":"Sheehan","year":"2023","journal-title":"Neuron"},{"issue":"5","key":"10.1016\/j.neurot.2026.e00859_bib81","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1080\/19336896.2016.1223003","article-title":"Tunneling nanotubes: a possible highway in the spreading of tau and other prion-like proteins in neurodegenerative diseases","volume":"10","author":"Abounit","year":"2016","journal-title":"Prion"},{"issue":"39","key":"10.1016\/j.neurot.2026.e00859_bib82","doi-asserted-by":"crossref","first-page":"E5427","DOI":"10.1073\/pnas.1516217112","article-title":"Transcellular spreading of huntingtin aggregates in the drosophila brain","volume":"112","author":"Babcock","year":"2015","journal-title":"Proc Natl Acad Sci"},{"issue":"12","key":"10.1016\/j.neurot.2026.e00859_bib83","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0083050","article-title":"Maintenance of basal levels of autophagy in huntington's disease mouse models displaying metabolic dysfunction","volume":"8","author":"Baldo","year":"2013","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00859_bib84","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/labinvest.2014.131","article-title":"Regulation of autophagy by protein post-translational modification","volume":"95","author":"Wani","year":"2015","journal-title":"Lab Invest"},{"issue":"2","key":"10.1016\/j.neurot.2026.e00859_bib85","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41419-019-1306-x","article-title":"CK2 inhibition with silmitasertib promotes methuosis-like cell death associated to catastrophic massive vacuolization of colorectal cancer cells","volume":"10","author":"Silva-Pavez","year":"2019","journal-title":"Cell Death Dis"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00859_bib86","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.tins.2014.09.003","article-title":"Autophagy in Huntington disease and huntingtin in autophagy","volume":"38","author":"Martin","year":"2015","journal-title":"Trends Neurosci"},{"key":"10.1016\/j.neurot.2026.e00859_bib87","article-title":"Targeting the autophagy-lysosomal pathway in Huntington disease: a pharmacological perspective","volume":"15","author":"Yang","year":"2023","journal-title":"Front Aging Neurosci [Internet]"},{"issue":"15","key":"10.1016\/j.neurot.2026.e00859_bib88","article-title":"Rapamycin reduces neuronal mutant huntingtin aggregation and ameliorates locomotor performance in Drosophila","author":"Roth","year":"2023","journal-title":"Front Aging Neurosci"},{"key":"10.1016\/j.neurot.2026.e00859_bib89","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.neuropharm.2016.04.041","article-title":"Activation of AMPK-induced autophagy ameliorates Huntington disease pathology in vitro","volume":"108","author":"Walter","year":"2016","journal-title":"Neuropharmacology"},{"issue":"5","key":"10.1016\/j.neurot.2026.e00859_bib90","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1080\/15548627.2023.2286116","article-title":"Correction of symptoms of Huntington disease by genistein through FOXO3-mediated autophagy stimulation","volume":"20","author":"Pierzynowska","year":"2024","journal-title":"Autophagy"},{"issue":"9","key":"10.1016\/j.neurot.2026.e00859_bib91","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1080\/17460441.2017.1349751","article-title":"Approaches for discovering novel bioactive small molecules targeting autophagy","volume":"12","author":"Hwang","year":"2017","journal-title":"Expet Opin Drug Discov"},{"issue":"6","key":"10.1016\/j.neurot.2026.e00859_bib92","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.molcel.2017.07.024","article-title":"VPS34 acetylation controls its lipid kinase activity and the initiation of canonical and non-canonical autophagy","volume":"67","author":"Su","year":"2017","journal-title":"Mol Cell"},{"issue":"3","key":"10.1016\/j.neurot.2026.e00859_bib93","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.112198","article-title":"Tumor suppressor p53 regulates heat shock factor 1 protein degradation in Huntington's disease","volume":"42","author":"Mansky","year":"2023","journal-title":"Cell Rep"},{"issue":"5","key":"10.1016\/j.neurot.2026.e00859_bib94","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0037929","article-title":"Impaired heat shock response in cells expressing full-length polyglutamine-expanded huntingtin","volume":"7","author":"Chafekar","year":"2012","journal-title":"PLoS One"},{"issue":"30","key":"10.1016\/j.neurot.2026.e00859_bib95","doi-asserted-by":"crossref","first-page":"E7081","DOI":"10.1073\/pnas.1801772115","article-title":"N6-Furfuryladenine is protective in Huntington's disease models by signaling huntingtin phosphorylation","volume":"115","author":"Bowie","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00859_bib96","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s12020-013-0133-6","article-title":"A critical role for CK2 in cytokine-induced activation of NF\u03baB in pancreatic \u03b2 cell death","volume":"47","author":"Jaksch","year":"2014","journal-title":"Endocrine"},{"key":"10.1016\/j.neurot.2026.e00859_bib97","article-title":"Astrocyte-mediated inflammatory responses in traumatic brain injury: mechanisms and potential interventions","volume":"16","author":"Zhang","year":"2025","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.neurot.2026.e00859_bib98","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.neuron.2020.08.012","article-title":"Astrocyte crosstalk in CNS inflammation","volume":"108","author":"Linnerbauer","year":"2020","journal-title":"Neuron"},{"key":"10.1016\/j.neurot.2026.e00859_bib99","doi-asserted-by":"crossref","unstructured":"Wakida NM, Lau AL, Nguyen J, Cruz GMS, Fote GM, Steffan JS, et al. Diminished LC3-Associated phagocytosis by Huntington's disease striatal astrocytes. J Huntingtons Dis. 11(1):25\u201333.","DOI":"10.3233\/JHD-210502"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00859_bib100","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-53414-9","article-title":"Co-stimulation with IL-1\u03b2 and TNF-\u03b1 induces an inflammatory reactive astrocyte phenotype with neurosupportive characteristics in a human pluripotent stem cell model system","volume":"9","author":"Hyv\u00e4rinen","year":"2019","journal-title":"Sci Rep"},{"issue":"8","key":"10.1016\/j.neurot.2026.e00859_bib101","doi-asserted-by":"crossref","first-page":"4065","DOI":"10.3390\/ijms22084065","article-title":"Neuroinflammatory response to TNF\u03b1 and IL1\u03b2 cytokines is accompanied by an increase in glycolysis in human astrocytes in vitro","volume":"22","author":"Pamies","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"7638","key":"10.1016\/j.neurot.2026.e00859_bib102","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/nature21029","article-title":"Neurotoxic reactive astrocytes are induced by activated microglia","volume":"541","author":"Liddelow","year":"2017","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.neurot.2026.e00859_bib103","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/jnc.15714","article-title":"Neurochemical correlates of synapse density in a Huntington's disease mouse model","volume":"164","author":"Zarate","year":"2023","journal-title":"J Neurochem"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00859_bib104","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1177\/1073858420972662","article-title":"Synaptic dysfunction in Huntington's disease: lessons from genetic animal models","volume":"28","author":"Cepeda","year":"2022","journal-title":"Neuroscientist"},{"issue":"4","key":"10.1016\/j.neurot.2026.e00859_bib105","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/cns.12844","article-title":"Disrupted striatal neuron inputs and outputs in Huntington's disease","volume":"24","author":"Reiner","year":"2018","journal-title":"CNS Neurosci Ther"},{"issue":"34","key":"10.1016\/j.neurot.2026.e00859_bib106","doi-asserted-by":"crossref","first-page":"5280","DOI":"10.1038\/sj.onc.1205640","article-title":"Functional interaction of protein kinase CK2 and c-Myc in lymphomagenesis","volume":"21","author":"Channavajhala","year":"2002","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.neurot.2026.e00859_bib107","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1096\/fj.02-0473rev","article-title":"One-thousand-and-one substrates of protein kinase CK2?","volume":"17","author":"Meggio","year":"2003","journal-title":"FASEB J"},{"issue":"2","key":"10.1016\/j.neurot.2026.e00859_bib108","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.bbrc.2004.07.158","article-title":"Protein kinase CK2 in postsynaptic densities: phosphorylation of PSD-95\/SAP90 and NMDA receptor regulation","volume":"322","author":"Soto","year":"2004","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"10.1016\/j.neurot.2026.e00859_bib109","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.celrep.2013.02.011","article-title":"Activated CaMKII couples GluN2B and casein kinase 2 to control synaptic NMDA receptors","volume":"3","author":"Sanz-Clemente","year":"2013","journal-title":"Cell Rep"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00859_bib110","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1093\/hmg\/8.1.115","article-title":"Length-dependent gametic CAG repeat instability in the Huntington's disease knock-in mouse","volume":"8","author":"Wheeler","year":"1999","journal-title":"Hum Mol Genet"},{"issue":"3","key":"10.1016\/j.neurot.2026.e00859_bib111","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1093\/hmg\/ddg056","article-title":"Mismatch repair gene Msh2 modifies the timing of early disease in HdhQ111 striatum","volume":"12","author":"Wheeler","year":"2003","journal-title":"Hum Mol Genet"},{"issue":"3","key":"10.1016\/j.neurot.2026.e00859_bib112","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.cell.2024.11.038","article-title":"Long somatic DNA-repeat expansion drives neurodegeneration in Huntington's disease","volume":"188","author":"Handsaker","year":"2025","journal-title":"Cell"},{"issue":"10","key":"10.1016\/j.neurot.2026.e00859_bib113","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1003930","article-title":"Mismatch repair genes Mlh1 and Mlh3 modify CAG instability in Huntington's disease mice: genome-wide and candidate approaches","volume":"9","author":"Pinto","year":"2013","journal-title":"PLoS Genet"},{"issue":"12","key":"10.1016\/j.neurot.2026.e00859_bib114","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1093\/hmg\/ddl125","article-title":"Genetic background modifies nuclear mutant huntingtin accumulation and HD CAG repeat instability in Huntington's disease knock-in mice","volume":"15","author":"Lloret","year":"2006","journal-title":"Hum Mol Genet"},{"issue":"4","key":"10.1016\/j.neurot.2026.e00859_bib115","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/70598","article-title":"Msh2 deficiency prevents in vivo somatic instability of the CAG repeat in Huntington disease transgenic mice","volume":"23","author":"Manley","year":"1999","journal-title":"Nat Genet"},{"issue":"2","key":"10.1016\/j.neurot.2026.e00859_bib116","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1003280","article-title":"MSH3 polymorphisms and protein levels affect CAG repeat instability in Huntington's disease mice","volume":"9","author":"Tom\u00e9","year":"2013","journal-title":"PLoS Genet"},{"issue":"9","key":"10.1016\/j.neurot.2026.e00859_bib117","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1093\/nar\/30.9.1959","article-title":"Phosphorylation of mismatch repair proteins MSH2 and MSH6 affecting MutS\u03b1 mismatch-binding activity","volume":"30","author":"Christmann","year":"2002","journal-title":"Nucleic Acids Res"},{"issue":"15_suppl","key":"10.1016\/j.neurot.2026.e00859_bib118","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1200\/jco.2011.29.15_suppl.3087","article-title":"Findings from the phase I clinical trials of CX-4945, an orally available inhibitor of CK2","volume":"29","author":"Marschke","year":"2011","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.neurot.2026.e00859_bib119","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1182\/blood.V120.21.2471.2471","article-title":"CX-4945, an orally bioavailable selective inhibitor of casein kinase 2 (CK2), exhibits anti-tumor activity in chronic lymphocytic leukemia and exhibits synergy when combined with the PI3K-\u0394 inhibitor GS-1101 or fludarabine","volume":"120","author":"Prins","year":"2012","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00859_bib120","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/leu.2013.232","article-title":"Activity of the clinical-stage CK2-specific inhibitor CX-4945 against chronic lymphocytic leukemia","volume":"28","author":"Martins","year":"2014","journal-title":"Leukemia"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747926000292?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747926000292?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T08:01:22Z","timestamp":1777622482000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747926000292"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":119,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S1878747926000292"],"URL":"https:\/\/doi.org\/10.1016\/j.neurot.2026.e00859","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Silmitasertib, an FDA-designated orphan CK2 inhibitor, ameliorates neuropathology and motor dysfunction in a Huntington's disease mouse model","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurot.2026.e00859","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of American Society for Experimental NeuroTherapeutics.","name":"copyright","label":"Copyright"}],"article-number":"e00859"}}